8-K: Aimfinity Investment Corp. I Details Business Combination Financials, Settles Underwriting Fees with Equity

Aimfinity Investment Corp. I (AIMUF) has filed an 8-K detailing the financial arrangements for its business combination with Docter Inc., including the settlement of deferred underwriting commissions and conversion of significant loans into equity.

Summary

• Aimfinity Investment Corp. I (AIMUF) entered into Satisfaction and Discharge of Indebtedness agreements with D. Boral Capital LLC and US Tiger Securities, Inc., the underwriters of its initial public offering.
• The original deferred underwriting commission of $2,817,500, due upon business combination completion, will now be settled with each underwriter receiving $80,000 in cash and 132,875 ordinary shares of the Purchaser (PubCo Ordinary Shares), valued at $10.00 per share, totaling $1,328,750 in shares per underwriter.
• An adjustment provision ensures that if the volume weighted average price (VWAP) of the PubCo Ordinary Shares before the registration statement filing is less than the $10.00 per share original value, the Company will compensate the underwriters in cash or additional PubCo Ordinary Shares.
• The business combination with Docter Inc. is scheduled to close on or about June 28, 2025, at which point PubCo will be renamed Inkwater Holding Inc.
• AIMUF's CEO and Chairman, I-Fa Chang, will transfer Inkrock Holding Limited to Purchaser in exchange for 687,054 Purchaser ordinary shares at $10.00 per share.
• Approximately $2.6 million of AIMUF's extension and working capital loans, primarily held by Mr. I-Fa Chang, will be converted into PubCo Ordinary Shares and warrants at $10.00 per unit/share at closing.
• Docter Inc. and Horn Enterprise Co., Ltd. note holders, including Mr. Hsin-Ming Huang (CEO of Docter) and Ms. Yi-Jun Ye, will convert approximately $0.6 million of outstanding principal and interest of loans into PubCo Ordinary Shares at $10.00 per share.
• Pro forma shareholder equity is estimated at approximately US$4.02 million as of June 30, 2025, after accounting for 1,072,957 Class A ordinary shares redeemed, the Inkrock purchase, and loan/commission conversions.
• The estimated loss for the 12 months from July 1, 2024, to June 30, 2025, due to burn rate, is approximately US$468,375.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative. While the business combination is progressing, the financial terms, including significant redemptions, the use of equity to settle deferred fees, and the conversion of substantial loans to equity, suggest financial constraints and potential dilution for existing shareholders. The pro forma equity is also notably reduced.

Positives

• The settlement of the deferred underwriting commission through a combination of cash and equity reduces immediate cash outflow for the company at the closing of the business combination.
• The adjustment provision for the underwriters' equity compensation provides a mechanism to ensure they receive the agreed-upon value, potentially stabilizing relationships with key financial partners.
• The conversion of significant outstanding loans into equity strengthens the combined entity's balance sheet by reducing debt obligations and conserving cash.

Negatives

• The settlement of deferred underwriting commissions with a significant equity component, rather than full cash, indicates potential cash constraints or a strategic preference for equity over cash at closing.
• The conversion of substantial loans into equity, while reducing debt, will result in dilution for existing shareholders.
• The exercise of redemption rights by holders of 1,072,957 Class A ordinary shares significantly reduced the company's cash in trust and resulted in a lower pro forma shareholder equity of approximately US$4.02 million, down from US$4,767,182 before redemptions.

Risks

• Risks related to the expected timing and likelihood of completion of the proposed business combination, including the risk that closing conditions may not be satisfied or waived, or regulatory approvals not obtained.
• Risks related to the ability of AIMUF and Docter to successfully integrate their businesses.
• The occurrence of any event, change, or other circumstances that could give rise to the termination of the applicable transaction agreements.
• The risk that there may be a material adverse change with respect to the financial position, performance, operations, or prospects of Docter or AIMUF.
• Risks related to disruption of management time from ongoing business operations due to the proposed transaction.
• The risk that any announcements relating to the proposed transaction could have adverse effects on the market price of AIMUF's securities.
• The risk that the proposed transaction and its announcement could have an adverse effect on Docter's ability to retain customers, key personnel, and maintain relationships with suppliers and customers.
• Risks relating to the health monitoring device industry, including governmental regulatory and enforcement changes, market competitions, and competitive product and pricing activity.
• Risks relating to the combined company's ability to enhance its products and services, execute its business strategy, expand its customer base, and maintain stable relationships with business partners.
• The potential for the VWAP of PubCo Ordinary Shares to be lower than the Original Aggregate Share Value, which would trigger additional compensation to underwriters in cash or further dilutive share issuance.

Future Outlook

The document indicates that the business combination between AIMUF and Docter is scheduled to close on or about June 28, 2025. Following the closing, the Purchaser (PubCo) will be renamed Inkwater Holding Inc. The company also plans to file a registration statement for the newly issued shares within 30 days from the closing and use commercially reasonable efforts to cause it to be declared effective by the SEC. There is a forward-looking statement regarding potential compensation to underwriters if the share price falls below a certain value prior to the registration statement filing.

Management Comments

• I-Fa Chang, CEO of Aimfinity Investment Corp. I, signed the report and the Satisfaction and Discharge agreements.
• Hsin-Ming Huang, CEO of Docter Inc., signed the Satisfaction and Discharge agreements.

Industry Context

This filing primarily concerns the financial and structural aspects of a SPAC business combination within the health monitoring device industry. The settlement of deferred underwriting fees with a significant equity component and the conversion of substantial loans to equity are common strategies in SPAC transactions, especially when managing cash flow or dealing with high redemption rates. The pro forma equity figures reflect the impact of redemptions, a prevalent challenge in the current SPAC market, which often leads to lower-than-expected cash proceeds for the combined entity.

Related Party Transactions

• AIMUF's CEO and Chairman, I-Fa Chang, is transferring Inkrock Holding Limited, a British Virgin Islands business company controlled by him, to Purchaser in exchange for 687,054 ordinary shares of Purchaser.
• Mr. I-Fa Chang, as the holder of certain promissory notes issued by the Company, agreed to convert up to $1.5 million of extension loan and working capital loan into units of the Company and convert all remaining working capital and extension loans outstanding (estimated at approximately $1.1 million) into PubCo Ordinary Shares.
• Mr. Hsin-Ming Huang, CEO of Docter and Horn Enterprise, and Ms. Yi-Jun Ye, who had previously loaned funds to Docter and/or Horn, agreed to convert all outstanding principal and interest of loans owed by Docter or Horn Enterprise into PubCo Ordinary Shares.

Stakeholder Impact

• **Shareholders**: Existing shareholders will experience dilution due to the issuance of new PubCo Ordinary Shares to underwriters, for the Inkrock acquisition, and for the conversion of outstanding loans. Shareholders who exercised redemption rights have exited their investment.
• **Underwriters (D. Boral Capital LLC and US Tiger Securities, Inc.)**: Will receive a mix of cash and equity for their deferred commission, with an adjustment mechanism to protect their equity value, indicating a shift from a pure cash payout to a more vested interest in the combined entity's future performance.
• **Creditors (Mr. I-Fa Chang, Docter Note Holders)**: Their loans are being converted into equity, transforming them from creditors to shareholders, which impacts their risk profile and potential returns.
• **Employees/Management**: The business combination and subsequent integration may lead to changes in organizational structure, though no specific impact on employees or management (beyond the CEO of Docter) is detailed in this filing.

Next Steps

• The business combination between AIMUF and Docter is scheduled to close on or about June 28, 2025.
• The Purchaser (PubCo) will be renamed Inkwater Holding Inc. upon consummation of the business combination.
• The Company shall cause a registration statement on Form F-1 for the Compensation Shares to be filed within 30 days from the Closing.
• The Company will use commercially reasonable efforts to cause the registration statement to be declared effective by the SEC.

Key Dates

Keywords

SEC filing, 8-K, business combination, merger, SPAC, de-SPAC, Aimfinity Investment Corp. I, Docter Inc., Inkwater Holding Inc., deferred underwriting commission, equity settlement, loan conversion, shareholder equity, redemption, dilution, financial restructuring, health monitoring device industry